Cargando…
Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes
There have been no reports on mortality in patients with markedly elevated aspartate aminotransferase (AST) levels from non-hepatic causes to date. This study aimed to determine the etiologies of markedly elevated AST levels > 400 U/L due to non-hepatic causes and to investigate the factors assoc...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821092/ https://www.ncbi.nlm.nih.gov/pubmed/36615110 http://dx.doi.org/10.3390/jcm12010310 |
_version_ | 1784865615604875264 |
---|---|
author | Han, Ji-Hee Kwak, Ji-Yoon Lee, Sang-Soo Kim, Hyun-Gyu Jeon, Hankyu Cha, Ra-Ri |
author_facet | Han, Ji-Hee Kwak, Ji-Yoon Lee, Sang-Soo Kim, Hyun-Gyu Jeon, Hankyu Cha, Ra-Ri |
author_sort | Han, Ji-Hee |
collection | PubMed |
description | There have been no reports on mortality in patients with markedly elevated aspartate aminotransferase (AST) levels from non-hepatic causes to date. This study aimed to determine the etiologies of markedly elevated AST levels > 400 U/L due to non-hepatic causes and to investigate the factors associated with mortality in these cases. This retrospective study included 430 patients with AST levels > 400 U/L unrelated to liver disease at two centers between January 2010 and December 2021. Patients were classified into three groups according to etiology: skeletal muscle damage, cardiac muscle damage, and hematologic disorder. Binary logistic regression analysis was performed to evaluate the factors associated with 30-day mortality. The most common etiology for markedly elevated AST levels was skeletal muscle damage (54.2%), followed by cardiac muscle damage (39.1%) and hematologic disorder (6.7%). The 30-day mortality rates for the skeletal muscle damage, cardiac muscle damage, and hematologic disorder groups were 14.2%, 19.5%, and 65.5%, respectively. The magnitude of the peak AST level significantly correlated with 30-day mortality, with rates of 12.8%, 26.7%, and 50.0% for peak AST levels < 1000 U/L, <3000 U/L, and ≥3000 U/L, respectively. In the multivariate analysis, cardiac muscle damage (odds ratio [OR] = 2.76, 95% confidence interval [CI] = 1.31–5.80), hematologic disorder (OR = 9.47, 95% CI = 2.95–30.39), peak AST < 3000 U/L (OR = 2.94, 95% CI = 1.36–6.35), and peak AST ≥ 3000 U/L (OR = 9.61, 95% CI = 3.54–26.08) were associated with increased 30-day mortality. Our study revealed three etiologies of markedly elevated AST unrelated to liver disease and showed that etiology and peak AST level significantly affected the survival rate. |
format | Online Article Text |
id | pubmed-9821092 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98210922023-01-07 Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes Han, Ji-Hee Kwak, Ji-Yoon Lee, Sang-Soo Kim, Hyun-Gyu Jeon, Hankyu Cha, Ra-Ri J Clin Med Article There have been no reports on mortality in patients with markedly elevated aspartate aminotransferase (AST) levels from non-hepatic causes to date. This study aimed to determine the etiologies of markedly elevated AST levels > 400 U/L due to non-hepatic causes and to investigate the factors associated with mortality in these cases. This retrospective study included 430 patients with AST levels > 400 U/L unrelated to liver disease at two centers between January 2010 and December 2021. Patients were classified into three groups according to etiology: skeletal muscle damage, cardiac muscle damage, and hematologic disorder. Binary logistic regression analysis was performed to evaluate the factors associated with 30-day mortality. The most common etiology for markedly elevated AST levels was skeletal muscle damage (54.2%), followed by cardiac muscle damage (39.1%) and hematologic disorder (6.7%). The 30-day mortality rates for the skeletal muscle damage, cardiac muscle damage, and hematologic disorder groups were 14.2%, 19.5%, and 65.5%, respectively. The magnitude of the peak AST level significantly correlated with 30-day mortality, with rates of 12.8%, 26.7%, and 50.0% for peak AST levels < 1000 U/L, <3000 U/L, and ≥3000 U/L, respectively. In the multivariate analysis, cardiac muscle damage (odds ratio [OR] = 2.76, 95% confidence interval [CI] = 1.31–5.80), hematologic disorder (OR = 9.47, 95% CI = 2.95–30.39), peak AST < 3000 U/L (OR = 2.94, 95% CI = 1.36–6.35), and peak AST ≥ 3000 U/L (OR = 9.61, 95% CI = 3.54–26.08) were associated with increased 30-day mortality. Our study revealed three etiologies of markedly elevated AST unrelated to liver disease and showed that etiology and peak AST level significantly affected the survival rate. MDPI 2022-12-30 /pmc/articles/PMC9821092/ /pubmed/36615110 http://dx.doi.org/10.3390/jcm12010310 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Han, Ji-Hee Kwak, Ji-Yoon Lee, Sang-Soo Kim, Hyun-Gyu Jeon, Hankyu Cha, Ra-Ri Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes |
title | Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes |
title_full | Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes |
title_fullStr | Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes |
title_full_unstemmed | Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes |
title_short | Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes |
title_sort | markedly elevated aspartate aminotransferase from non-hepatic causes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821092/ https://www.ncbi.nlm.nih.gov/pubmed/36615110 http://dx.doi.org/10.3390/jcm12010310 |
work_keys_str_mv | AT hanjihee markedlyelevatedaspartateaminotransferasefromnonhepaticcauses AT kwakjiyoon markedlyelevatedaspartateaminotransferasefromnonhepaticcauses AT leesangsoo markedlyelevatedaspartateaminotransferasefromnonhepaticcauses AT kimhyungyu markedlyelevatedaspartateaminotransferasefromnonhepaticcauses AT jeonhankyu markedlyelevatedaspartateaminotransferasefromnonhepaticcauses AT charari markedlyelevatedaspartateaminotransferasefromnonhepaticcauses |